High PD-L1 expression in both intratumoral or neoplastic inflammatory cells is linked to poor prognosis in HCC patients, indicating the potential of PD-1/PD-L1 signaling as a therapeutic target in immunotherapy [38]. This evidence concerns the gene CD274 and hepatocellular carcinoma.